The present longitudinal prospective study suggests that elevation of plasma Lp-PLA2 (activity), Lp-PLA2 (mass), and CRP, are all markers of subclinical disease susceptibility long time before diagnosis of PAD. This evidence concerns the gene CRP and peripheral arterial disease.